Advancing Therapeutic Discovery With Reproducible High Throughput Electroporation

Pressure to move faster in cell therapy and drug discovery is real, and the bottlenecks are well known: high costs, extended timelines, and the persistent difficulty of transfecting complex cell types at scale. High-throughput electroporation addresses several of these challenges directly. A platform capable of processing 96 samples in under three minutes, with independent optimization per sample and minimal material waste, changes what is feasible in early-stage screening workflows. For CAR-T development specifically, non-viral engineering via CRISPR-Cas9 knock-in becomes more accessible when you can run those experiments with consistent reproducibility across a full plate. The ability to fine-tune energy delivery across diverse cell populations, including immune cells historically considered difficult to transfect, adds meaningful flexibility.

Scalability is built in from the start, so the conditions you optimize at discovery scale translate forward into GMP-compliant manufacturing without starting over. If your team is navigating the tradeoffs between speed, cost, and quality in cell therapy programs, watch the on-demand webinar to see how these workflows perform across real-world applications.